Stop STALLING Act
- Last Action
- 4/10/2025
Actions
- 2025-04-10Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
- 2025-04-10Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- 2025-04-10Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- 2025-04-03Committee on the Judiciary. Ordered to be reported without amendment favorably.
- 2025-03-24Read twice and referred to the Committee on the Judiciary.
- 2025-03-24Introduced in Senate
CRS Summary
As of 2025-03-24 (00)
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Cosponsors (6)
- Chuck Grassley (R-IA)
- Richard Durbin (D-IL)
- Richard Blumenthal (D-CT)
- Ted Cruz (R-TX)
- Peter Welch (D-VT)
- Cory Booker (D-NJ)
Subjects
- Administrative remedies
- Business ethics
- Civil actions and liability
- Competition and antitrust
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)
- Licensing and registrations
- Prescription drugs
- Public participation and lobbying
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.